

1 **The effect of metabolic traits on oral and oropharyngeal cancer**
2 **risk: a Mendelian randomization analysis**

3

4 Mark Gormley, BDS* ^{1,2}, Tom Dudding, PhD², Steven J Thomas, PhD², Jessica Tyrrell, PhD³,
5 Andrew R Ness, PhD⁴, Miranda Pring, PhD², Danny Legge, PhD⁵, George Davey Smith, FRS¹,
6 Rebecca C Richmond, PhD¹, Emma E Vincent, PhD^{1,5§}, Caroline Bull, PhD^{1,5§}

7 ¹ MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol,
8 Bristol, UK.

9 ² Bristol Dental Hospital and School, University of Bristol, Bristol, UK.

10 ³ University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.

11 ⁴ University Hospitals Bristol and Weston NHS Foundation Trust National Institute for Health Research Bristol
12 Biomedical Research Centre, University of Bristol, Bristol, UK

13 ⁵ Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

14 § Joint senior authors

15 * Corresponding author: mark.gormley@bristol.ac.uk

16

17

18

19

20 **Abstract**

21

22 **Introduction**

23 A recent World Health Organization report states that at least 40% of all cancer cases may
24 be preventable, with smoking, alcohol consumption and obesity identified as three of the
25 most important modifiable lifestyle factors. Established risk factors for head and neck
26 cancer include tobacco use, alcohol consumption and human papillomavirus infection.
27 Given the significant decline in smoking rates, particularly within developing countries,
28 other potentially modifiable risk factors warrant investigation. Obesity and related
29 metabolic disorders such as type 2 diabetes and hypertension have all been associated with
30 head and neck cancer risk in multiple observational studies. However, obesity has also been
31 correlated with other major head and neck cancer risk factors such as smoking, meaning
32 independent effects are difficult to establish. Furthermore, selection bias, confounding or
33 reverse causality may explain the findings from observational studies.

34

35 **Methods**

36 To overcome the challenges of observational studies, we conducted two-sample Mendelian
37 randomization (inverse variance weighted (IVW) method) using genetic variants which were
38 robustly associated with obesity, T2D and hypertension in genome-wide association studies
39 (GWAS). Outcome data was taken from the largest available GWAS of 6,034 oral and
40 oropharyngeal cases, with 6,585 controls.

41

42 **Results**

43 We found limited evidence of a causal effect of genetically proxied body mass index (OR
44 IVW 0.89, 95%CI 0.72–1.09, $p = 0.26$ per 1 SD in BMI (4.81 kg/m²)) on combined oral and
45 oropharyngeal cancer risk. Similarly, there was limited evidence for genetically-proxied T2D
46 (OR IVW 0.92, 95%CI 0.84–1.01, $p = 0.09$ per 1-log unit higher odds of T2D), or related traits
47 including fasting glucose and insulin. Higher HbA1c resulted in a weak protective effect on
48 combined oral and oropharyngeal cancer risk (OR IVW 0.56, 95%CI 0.32–1.00, $p = 0.05$ per
49 1-log-unit % higher HbA1c), which was not robust to sensitivity testing. Finally, there was
50 limited evidence for an effect of systolic blood pressure on combined oral and
51 oropharyngeal cancer risk (OR IVW 1.00, 95%CI 0.97–1.03, $p = 0.89$ per 1 unit mmHg
52 increase). Smoking also appears to act as a mediator in the relationship between obesity
53 and HNC in instrument-risk factor analyses.

54

55 **Conclusion**

56 This analysis suggests the possibility that the effect of metabolic disorders may have been
57 previously overestimated in observational studies. However, these cannot be directly
58 compared given the differences in methodologies and the interpretation of estimates.

59

60

61

62

63

64

65

66 Introduction

67

68 Head and neck squamous cell carcinoma (HNC), which includes cancers of the oral cavity
69 and oropharynx is the 7th most common cancer, accounting for more than 660,000 new
70 cases and 325,000 deaths annually worldwide ^{1,2}. Established risks include tobacco use,
71 alcohol consumption ³ and human papillomavirus (HPV) infection, mainly associated with
72 oropharyngeal cancer and thought to be sexually transmitted ⁴. A recent World Health
73 Organization (WHO) report states that at least 40% of all cancer cases may be preventable,
74 with smoking, alcohol consumption and obesity identified as three of the most important
75 modifiable lifestyle factors ⁵. Smoking behaviour is declining, particularly in developing
76 countries and it has been projected that obesity could even supersede smoking as the
77 primary driver of cancer in the coming decades ⁵. Despite changes in smoking rates, the
78 incidence of HNC continues to rise and a changing aetiology has been proposed ^{6,7}.
79 Therefore, less established risks such as obesity and its related metabolic traits warrant
80 investigation in HNC. However, obesity has been correlated with other HNC risk factors such
81 as smoking ⁸, alcohol ⁹ and educational attainment ¹⁰, meaning independent effects are
82 difficult to establish.

83

84 Obesity is now considered to increase the risk of at least 13 different types of cancer
85 including breast, colorectal, gastric and oesophageal ¹¹, but the effect on HNC risk remains
86 unclear ⁵. Public health strategies have been unsuccessful in addressing the current obesity
87 epidemic at the population level, which could result in more cancer cases in the years to
88 come ¹². Obesity and related metabolic traits such as type 2 diabetes (T2D), hypertension
89 and dyslipidaemia have all been associated with head and neck cancer in multiple

90 observational studies. In the largest pooled analysis, obesity defined by higher body mass
91 index (BMI) was associated with a protective effect for HNC in current smokers (hazard ratio
92 (HR) 0.76, 95% confidence intervals (95%CI) 0.71–0.82, $p < 0.0001$, per 5 kg/m²) and
93 conversely, a higher risk in never smokers (HR 1.15, 95%CI 1.06–1.24 per 5 kg/m², $p <$
94 0.001)¹³. In the same study, a greater waist circumference (WC) (HR 1.04, 95%CI 1.03–
95 1.05 per 5 cm, $p < 0.001$) and waist-to-hip ratio (WHR) (HR 1.07, 95%CI 1.05–1.09 per 0.1
96 unit, $p < 0.001$) were associated with increased HNC risk, which did not vary by smoking
97 status¹³. However, more recent cohort studies have failed to show a clear association
98 between BMI and HNC¹⁴⁻¹⁸. A meta-analysis of observational studies investigating T2D with
99 oral and oropharyngeal subsites, showed an increased risk ratio (RR) of 1.15, 95%CI 1.02–
100 1.29, $P_{heterogeneity} = 0.277$ ¹⁹, a result which is consistent with more recent independent
101 cohorts^{14,20-22}. Hypertension (defined as a systolic blood pressure (SBP) > 130 mmHg or
102 diastolic blood pressure (DBP) > 85 mmHg), has been correlated with head and neck cancer
103 risk across multiple studies²¹⁻²⁵. Nonetheless, selection bias, confounding, or reverse
104 causation may explain the findings from these studies.

105

106 Mendelian randomization (MR) is an analytical approach which attempts to overcome the
107 challenges of conventional epidemiological studies. The method uses germline genetic
108 single nucleotide polymorphisms (SNPs), which are randomly assorted during meiosis (and
109 fixed at conception), to estimate the causal effects of exposures on disease outcomes²⁶⁻²⁸.
110 Using MR, we recently found limited evidence for a role of circulating lipid traits in oral and
111 oropharyngeal cancer risk²⁹, however other metabolic traits remain untested in an MR
112 framework. Here, we employ a two-sample MR approach, integrating summary-level
113 genetic data from the largest available GWAS for metabolic traits, including obesity

114 measures (BMI, WC, WHR), glycaemic traits (T2D, glycated haemoglobin (HbA_{1c}), fasting
115 glucose (FG), fasting insulin (FI)), and blood pressure (SBP, DBP) to evaluate their causal
116 effect on oral and oropharyngeal cancer risk. Given the potential correlation of metabolic
117 traits and established HNC risk factors, further evaluation of instrument-risk factor effects
118 including smoking, alcohol, risk tolerance (as a proxy for sexual behaviour), and educational
119 attainment was carried out using MR.

120


121 Methods

122

123 Two-sample MR was performed using published summary-level data from the largest
124 available GWAS for each metabolic trait. MR makes three key assumptions, as described in

125 **Fig. 1** ^{26,27}.

126



127

128 **Figure 1.** Directed acyclic graph (DAG) depicting Mendelian randomization applied to this

129 study

130

131 Genetic variants (G) act as proxies or instruments to investigate if an exposure (X), is associated with a trait
132 e.g., body mass index or disease outcome (Y) e.g., oral/oropharyngeal cancer. Causal inference can be made
133 between X and Y if the following conditions are upheld:

134 (1) G is a valid instrument, reliably associated with X ('relevance');

135 (2) no measured (C) or unmeasured (U) confounding of the association between G and the Y
136 ('exchangeability');

137 (3) there is no independent association of G with Y, except through X ('exclusion restriction principle').

138

139 **Exposure summary statistics for metabolic traits**

140

141 To instrument metabolic traits, we selected genetic variants associated ($p < 5 \times 10^{-8}$) with
142 traits of interest identified by previously conducted GWAS (**Supplementary Data 1**).

143 Clumping was performed to ensure single nucleotide polymorphisms (SNPs) in each
144 instrument were independent (linkage disequilibrium $R^2 < 0.001$). Following clumping,
145 genetic instruments were comprised of: 312 SNPs for BMI, from a GWAS meta-analysis of

146 806,834 individuals of European ancestry, including the Genetic Investigation

147 of ANthropometric Traits (GIANT) consortium and UK Biobank³⁰; 45 SNPs for WC, extracted

148 from the same GWAS³⁰; 209 SNPs for WHR extracted from a GWAS meta-analysis describing

149 224,459 individuals of mainly European ancestry³¹; 275 SNPs for T2D from the DIAMANTE

150 (DIAbetes Meta-ANalysis of Trans-Ethnic association studies) consortium of 228,499 cases

151 and 1,178,783 controls³²; 33 SNPs for FG and 18 SNPs for FI, obtained from a GWAS

152 published by the MAGIC (Meta-Analyses of Glucose and Insulin-Related Traits) Consortium

153 (N = 151,188 and 105,056 individuals, respectively)³³; 58 SNPs for HbA_{1c}, taken from a

154 meta-analyses of 159,940 individuals from 82 cohorts of European, African, East Asian, and

155 South Asian ancestry³⁴; Finally, 105 and 78 SNPs for SBP and DBP, respectively, were
156 extracted from a GWAS meta-analysis of over 1 million participants in UK Biobank and the
157 International Consortium of Blood Pressure Genome Wide Association Studies (ICBP)³⁵
158 **(Supplementary Data 1)**.

159

160 **Outcome summary statistics for oral and oropharyngeal cancer**

161

162 We estimated the effects of metabolic traits on risk of oral and oropharyngeal cancer by
163 extracting exposure SNPs **(Supplementary Data 1)** from the largest available GWAS
164 performed on 6,034 cases and 6,585 controls from 12 studies which were part of the
165 Genetic Associations and Mechanisms in Oncology (GAME-ON) Network³⁶. Full details of
166 the included studies, as well as the genotyping and imputation performed, have been
167 described previously^{36,37}. In brief, the study population included participants from Europe
168 (45.3%), North America (43.9%) and South America (10.8%). Cancer cases comprised the
169 following the International Classification of Diseases (ICD) codes: oral cavity (C02.0-C02.9,
170 C03.0-C03.9, C04.0-C04.9, C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9),
171 hypopharynx (C13.0-C13.9), overlapping (C14 and combination of other sites) and 25 cases
172 with unknown ICD code (other). A total of 954 individuals with cancers of hypopharynx,
173 unknown code or overlapping cancers were excluded. Genomic DNA isolated from blood or
174 buccal cells was genotyped at the Center for Inherited Disease Research (CIDR) using an
175 Illumina OncoArray, custom designed for cancer studies by the OncoArray Consortium³⁸.
176 Principle components analysis was performed using approximately 10,000 common markers
177 in low LD ($r^2 < 0.004$), minor allele frequency (MAF) > 0.05 and 139 population outliers were
178 removed.

179

180 Given the differential association of potential risk factors at each subsite (i.e. smoking,
181 alcohol and HPV infection)⁶, we performed stratified MR analyses for oral and
182 oropharyngeal cancer to evaluate potential heterogeneity in effects. For this, we used
183 GWAS summary data on a subset of 2,990 oral and 2,641 oropharyngeal cases and the 6,585
184 common controls in the GAME-ON GWAS ³⁶.

185

186 **Statistical analysis**

187

188 Two-sample MR was conducted using the “TwoSampleMR” package in R (version 3.5.3), by
189 integrating SNP associations for each metabolic trait (exposure, sample 1) with those for
190 oral and oropharyngeal cancer in GAME-ON (outcome, sample 2). We only used genetic
191 variants reaching GWAS significance ($p < 5 \times 10^{-8}$). The nearest gene was identified using
192 SNPsnap and a distance of +/- 500 kb ³⁹. Firstly, metabolic trait-associated SNPs were
193 extracted from oral and oropharyngeal cancer summary statistics. Exposure and outcome
194 summary statistics were harmonised using the “*harmonise_data*” function of the
195 TwoSampleMR package so that variant effect estimates corresponded to the same allele.
196 Palindromic SNPs were identified and corrected using allele frequencies where possible
197 (alleles were aligned when minor allele frequencies were < 0.3 , or were otherwise
198 excluded). For each SNP in each exposure, individual MR effect-estimates were calculated
199 using the Wald method (SNP-outcome beta/SNP-exposure beta) ⁴⁰. Multiple SNPs were then
200 combined into multi-allelic instruments using random-effects inverse-variance weighted
201 (IVW) meta-analysis.

202

203 IVW estimates may be vulnerable to bias if genetic instruments are invalid and are only
204 unbiased in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced
205 ⁴¹. We therefore performed additional sensitivity analyses to evaluate the potential for
206 unbalanced horizontal pleiotropy using weighted median ⁴², weighted mode ⁴³ and MR-
207 Egger ⁴⁴ methods which are described in detail elsewhere ⁴⁵. In short, the weighted median
208 stipulates that at least 50% of the weight in the analysis stems from valid instruments.
209 Weighted mode returns an unbiased estimate of the causal effect if the cluster with the
210 largest weighted number of SNPs for the weighted model are all valid instruments.
211 Instruments are weighted by the inverse variance of the SNP-outcome association.⁴³
212
213 Finally, MR-Egger provides reliable effect estimates even if variants are invalid and the
214 Instrument Strength Independent of Direct Effect (InSIDE) assumption is violated ⁴⁴. The
215 InSIDE assumption states that the association between genetic instrument and exposure
216 should not be correlated with an independent path from instrument to the outcome. In the
217 presence of unbalanced pleiotropy when the InSIDE assumption is violated, then the MR-
218 Egger result may be biased ⁴⁵. Gene variants must be valid instruments and where there was
219 evidence of violation of the negligible measurement error (NOME) assumption ⁴⁶, this was
220 assessed using the I^2 statistic and MR-Egger was performed with simulation extrapolation
221 (SIMEX) correction for bias adjustment ⁴⁶. The variance of each trait explained by the genetic
222 instrument (R^2) was estimated and used to perform power calculations ⁴⁷. F-statistics were
223 also generated. An F-statistic lower than 10 was interpreted as indicative of a weak
224 instrument bias ⁴⁸. To further assess the robustness of MR estimates, we examined evidence
225 of heterogeneity across individual SNPs using the Cochran Q-statistic, which indicates the
226 presence of invalid instruments (e.g., due to horizontal pleiotropy), if Q is much larger than

227 its degrees of freedom (No. of instrumental variables minus 1)⁴⁹. MR-PRESSO (Mendelian
228 Randomization Pleiotropy RESidual Sum and Outlier) was used to detect and correct for
229 potential outliers (where Q-statistic $p < 0.05$)⁵⁰.

230

231 **Instrument-risk factor effects**

232

233 Where there was evidence for an effect of a metabolic trait on oral or oropharyngeal cancer
234 risk in the primary MR analysis, we conducted further evaluation of the metabolic
235 instruments onto established HNC risk factors using two-sample MR. The largest available
236 GWAS were used for smoking initiation (a binary phenotype indicating whether an
237 individual had ever smoked in their life versus never smokers) ($n=1,232,091$) and alcoholic
238 drinks per week (defined as the average number of drinks per week aggregated across all
239 types of alcohol, $n=941,280$) from the GWAS and Sequencing Consortium of Alcohol and
240 Nicotine use (GSCAN) study⁵¹. Summary statistics were also obtained from a GWAS of
241 general risk tolerance ($n=939,908$), derived from a meta-analysis of UK Biobank
242 ($n=431,126$) binary question “*Would you describe yourself as someone who takes risks?*”
243 and the 23andMe ($n=508,782$) question “*Overall, do you feel comfortable or uncomfortable*
244 *taking risks?*”. The GWAS of risk tolerance was based on one’s tendency or willingness to
245 take risks, making them more likely to engage in risk-taking behaviours more generally⁵². A
246 strong genetic correlation between sexual behaviours and risk tolerance has been shown
247 previously⁵³. Finally, given the known association between HNC and lower socioeconomic
248 position, we used MR to examine educational attainment (defined by years of schooling)⁵⁴.
249 Outcome beta estimates reflect the standard deviation of the phenotype.

250

251 **Results**

252

253 F-statistics of genetic instruments for metabolic traits ranged from 33.3 – 133.6, indicating
254 sufficient instrument strength for MR analyses (**Supplementary Table 1**). Genetic
255 instruments were estimated to explain between 0.5% (FI) and 4% (BMI) of their respective
256 metabolic trait (**Supplementary Table 1**). Based on the results of prior observational studies
257 we would expect to detect OR of >1.10 for a clinically meaningful effect of metabolic traits
258 on oral and oropharyngeal cancer. **Supplementary Fig. 1A-C** displays power estimates for
259 MR analyses. In analyses where BMI was the exposure, we had 70% power to detect an
260 association with an OR of 1.2 or more at an α of 0.05 for combined oral and oropharyngeal
261 cancer. Power was lower for other metabolic traits and reduced when stratifying analyses
262 by subsite (**Supplementary Fig. 1**).

263

264 *Estimated effect of adiposity on oral and oropharyngeal cancer risk*

265 There was limited evidence of an effect of higher BMI or WHR on combined oral and
266 oropharyngeal cancer (OR IVW 0.89, 95%CI 0.72–1.09, $p = 0.26$, per 1 SD in BMI (4.81 kg/m²)
267 and OR IVW 0.98, 95%CI 0.74–1.29, $p = 0.88$, per 1 SD in WHR (0.10 unit)) (**Table 1; Fig. 2;**
268 **Supplementary Fig. 2 & 3**). Results were consistent when analyses were stratified by subsite
269 (**Table 1**). WC, another measure of adiposity did show a protective direction of effect (OR
270 IVW 0.73, 95%CI 0.52–1.02, $p = 0.07$, per 1 SD increase in WC (0.09 unit)), particularly in the
271 oropharyngeal subsite (OR IVW 0.66, 95%CI 0.43–1.01, $p = 0.06$, per 1 SD increase in WC
272 (0.09 unit)) (**Table 1; Fig. 2; Supplementary Fig. 4**).

273

274 *Estimated effect of glycaemic traits on oral and oropharyngeal cancer risk*

275 There was limited evidence for an effect of genetically-proxied T2D on combined oral and
276 oropharyngeal cancer (OR IVW 0.92, 95%CI 0.84–1.01, $p = 0.09$, per 1-log unit higher odds of
277 T2D (**Table 1; Fig. 2; Supplementary Fig. 5**). Traits related to diabetes, including HbA_{1c}
278 resulted in a weak protective effect on combined oral and oropharyngeal cancer risk (OR
279 IVW 0.56, 95%CI 0.32–1.00, $p = 0.05$, per 1-log-unit % higher HbA_{1c}), which remained only in
280 the oral subsite (OR IVW 0.48, 95%CI 0.24–0.93, $p = 0.03$, per 1-log-unit % higher HbA_{1c})
281 following stratification (**Table 1; Fig. 2; Supplementary Fig. 6**). Conversely, there was limited
282 evidence of an effect for FG (OR IVW 1.06, 95%CI 0.68–1.66, $p = 0.79$, per 1-log unit increase
283 in mmol/L fasting glucose) (**Table 1; Fig. 2; Supplementary Fig. 7**) or FI (OR IVW 0.81, 95%CI
284 0.23–2.89, $p = 0.75$, per 1-log unit increase in mmol/L fasting insulin) on combined oral and
285 oropharyngeal cancer risk (**Table 1; Fig. 2; Supplementary Fig. 8**)

286

287 *Estimated effect of increased blood pressure oral and oropharyngeal cancer risk*

288 Finally, there was limited evidence for an effect of SBP on risk of combined oral and
289 oropharyngeal cancer (OR IVW 1.00, 95%CI 0.97–1.03, $p = 0.89$, per 1 unit mmHg increase in
290 systolic blood pressure) (**Table 1; Fig. 2; Supplementary Fig. 9**), which did not change when
291 stratified by subsite. However, there was some weak evidence for a protective effect of DBP
292 on risk of combined oral and oropharyngeal cancer (OR IVW 0.93, 95%CI 0.87–1.00, $p = 0.05$,
293 per 1 unit mmHg increase in diastolic blood pressure) (**Table 1; Fig. 2; Supplementary Fig.**
294 **10**).

295 **Table 1.** Mendelian randomization results of genetically-proxied metabolic traits with risk of oral and oropharyngeal cancer in GAME-ON

Exposure	Outcome	Exposure/ Outcome source	Outcome N	Number of SNPs	IVW		Weighted median		Weighted mode		MR-Egger	
					OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P
BMI	Oral and oropharyngeal cancer combined	Pulit <i>et al.</i> GWAS ³⁰ / GAME-ON ³⁶	6,034	272	0.89 (0.72, 1.09)	0.26	0.71 (0.50, 1.00)	0.05	0.63 (0.37, 1.04)	0.07	0.66 (0.40, 1.10)	0.11
	Oral cancer		2,990	272	0.92 (0.71, 1.19)	0.53	0.83 (0.55, 1.28)	0.40	0.79 (0.38, 1.62)	0.52	0.75 (0.39, 1.41)	0.37
	Oropharyngeal cancer		2,641	272	0.89 (0.68, 1.15)	0.36	0.75 (0.50, 1.13)	0.17	0.53 (0.27, 1.03)	0.06	0.56 (0.29, 1.07)	0.08
WC	Oral and oropharyngeal cancer combined	Pulit <i>et al.</i> GWAS ³⁰ / GAME-ON ³⁶	6,034	43	0.73 (0.52, 1.02)	0.07	0.64 (0.40, 1.05)	0.08	0.67 (0.36, 1.26)	0.22	0.43 (0.17, 1.08)	0.08
	Oral cancer		2,990	43	0.82 (0.53, 1.26)	0.36	0.66 (0.36, 1.21)	0.18	0.67 (0.32, 1.39)	0.29	0.54 (0.17, 1.76)	0.31
	Oropharyngeal cancer		2,641	43	0.66 (0.43, 1.01)	0.06	0.56 (0.30, 1.05)	0.07	0.37 (0.17, 0.83)	0.02	0.30 (0.09, 0.98)	0.05
WHR	Oral and oropharyngeal cancer combined	Shungin <i>et al.</i> GWAS ³¹ / GAME-ON ³⁶	6,034	176	0.98 (0.74, 1.29)	0.88	0.98 (0.64, 1.49)	0.92	0.95 (0.45, 2.00)	0.89	1.80 (0.87, 3.71)	0.11
	Oral cancer		2,990	176	1.18 (0.84, 1.65)	0.35	1.00 (0.58, 1.73)	0.99	0.69 (0.29, 1.67)	0.41	2.49 (1.02, 6.12)	0.05
	Oropharyngeal cancer		2,641	176	0.83 (0.59, 1.14)	0.25	0.88 (0.51, 1.50)	0.63	0.93 (0.37, 2.30)	0.87	1.19 (0.50, 2.86)	0.70
T2D	Oral and oropharyngeal cancer combined	Vujkovic <i>et al.</i> GWAS ³² / GAME-ON ³⁶	6,034	254	0.92 (0.84, 1.01)	0.09	0.85 (0.74, 0.97)	0.02	0.84 (0.71, 1.01)	0.06	0.91 (0.77, 1.09)	0.31
	Oral cancer		2,990	254	0.94 (0.84, 1.05)	0.27	0.84 (0.72, 0.99)	0.04	0.82 (0.66, 1.02)	0.08	0.88 (0.71, 1.08)	0.22
	Oropharyngeal cancer		2,641	254	0.94 (0.84, 1.05)	0.27	0.89 (0.73, 1.10)	0.29	1.02 (0.80, 1.30)	0.88	1.00 (0.81, 1.24)	0.99
HbA _{1c}	Oral and oropharyngeal cancer combined	Wheeler <i>et al.</i> GWAS ³⁴ / GAME-ON ³⁶	6,034	37	0.56 (0.32, 1.00)	0.05	0.52 (0.23, 1.20)	0.12	0.54 (0.24, 1.21)	0.14	0.37 (0.13, 1.05)	0.07
	Oral cancer		2,990	37	0.48 (0.24, 0.93)	0.03	0.51 (0.18, 1.41)	0.19	0.44 (0.15, 1.29)	0.14	0.30 (0.09, 1.03)	0.06
	Oropharyngeal cancer		2,641	37	0.66 (0.31, 1.40)	0.28	0.49 (0.15, 1.57)	0.23	0.57 (0.18, 1.85)	0.35	0.43 (0.11, 1.68)	0.23
	Oral and oropharyngeal		6,034	28	1.06 (0.68, 1.66)	0.79	1.20 (0.62, 2.30)	0.59	1.13 (0.60, 2.12)	0.71	1.11 (0.48, 2.56)	0.80

FG	cancer combined	Lagou <i>et al.</i> GWAS ³³ / GAME-ON ³⁶											
	Oral cancer		2,990	28	1.05 (0.58, 1.92)	0.87	1.15 (0.48, 2.72)	0.75	0.99 (0.44, 2.23)	0.99	1.25 (0.39, 4.01)	0.70	
	Oropharyngeal cancer		2,641	28	1.39 (0.77, 2.51)	0.28	1.24 (0.51, 3.03)	0.63	1.36 (0.59, 3.18)	0.48	1.38 (0.45, 4.18)	0.58	
FI	Oral and oropharyngeal cancer combined	Lagou <i>et al.</i> GWAS ³³ / GAME-ON ³⁶	6,034	17	0.81 (0.23, 2.89)	0.75	0.75 (0.20, 2.87)	0.68	0.60 (0.03, 10.79)	0.74	0.11 (0.001, 22.47)	0.43	
	Oral cancer		2,990	17	0.96 (0.22, 4.16)	0.96	0.46 (0.08, 2.47)	0.37	0.45 (0.01, 19.02)	0.68	0.21 (0.0004, 107.21)	0.63	
	Oropharyngeal cancer		2,641	17	0.68 (0.16, 2.87)	0.59	0.66 (0.12, 3.67)	0.63	0.48 (0.05, 4.99)	0.55	0.09 (0.0002, 40.04)	0.45	
SBP	Oral and oropharyngeal cancer combined	Evangelou <i>et al.</i> GWAS ³⁵ / GAME-ON ³⁶	6,034	83	1.00 (0.97, 1.03)	0.89	0.99 (0.94, 1.03)	0.55	0.98 (0.88, 1.09)	0.66	1.06 (0.92, 1.23)	0.39	
	Oral cancer		2,990	83	1.01 (0.96, 1.06)	0.74	0.99 (0.93, 1.04)	0.65	0.95 (0.84, 1.08)	0.48	1.09 (0.90, 1.33)	0.37	
	Oropharyngeal cancer		2,641	83	0.99 (0.95, 1.03)	0.65	0.99 (0.94, 1.05)	0.77	1.00 (0.88, 1.13)	0.94	1.03 (0.87, 1.23)	0.71	
DBP	Oral and oropharyngeal cancer combined	Evangelou <i>et al.</i> GWAS ³⁵ / GAME-ON ³⁶	6,034	64	0.93 (0.87, 1.00)	0.05	0.94 (0.86, 1.04)	0.22	1.10 (0.88, 1.38)	0.42	0.99 (0.80, 1.24)	0.95	
	Oral cancer		2,990	64	0.95 (0.87, 1.04)	0.26	0.96 (0.86, 1.07)	0.45	1.17 (0.88, 1.56)	0.28	0.97 (0.74, 1.27)	0.81	
	Oropharyngeal cancer		2,641	64	0.92 (0.84, 1.00)	0.05	0.94 (0.84, 1.05)	0.29	1.10 (0.86, 1.41)	0.45	1.00 (0.75, 1.30)	0.93	

296

297

Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, *p*-value; BMI, body mass index; WC, waist circumference; WHR, waist-hip ratio; T2D, type 2 diabetes mellitus; FG, fasting

298

glucose; FI, fasting insulin; HbA_{1c}, glycated haemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically predicted BMI (4.81 kg/m²),


299

WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA_{1c} (1-log-unit % higher glycated

300

haemoglobin), SBP (1 unit mmHg increase) and DBP (1 unit mmHg increase).

301 **Figure 2.** Mendelian randomization results of genetically-proxied metabolic disorders with
 302 risk of oral and oropharyngeal cancer including sensitivity analyses in GAME-ON
 303



304

305

306 Abbreviations: IVW, inverse variance weighted; OR, odds ratio with 95% confidence intervals; BMI, body mass index; WC, waist
 307 circumference; WHR, waist-hip ratio; T2D, type 2 diabetes mellitus; FG, fasting glucose; FI, fasting insulin; HbA1c, glycated haemoglobin;
 308 SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically
 309 predicted BMI (4.81 kg/m²), WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L
 310 fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA1c (1-log-unit % higher glycated haemoglobin), SBP (1 unit mmHg
 311 increase) and DBP (1 unit mmHg increase).

312

313 Sensitivity analyses

314

315 We conducted MR Egger, weighted median, and weighted mode analyses in addition to IVW

316 (**Table 1; Fig. 2**). The results of these analyses generally followed the same pattern as the

317 IVW results reported above, however, there were a number of exceptions. The results for
318 HbA1c were not robust to sensitivity testing ($p > 0.05$ across methods) (**Table 1; Fig. 2**). In
319 the analysis of T2D on combined oral and oropharyngeal cancer, the weighted median result
320 provided evidence for a weak protective effect (OR weighted median 0.85, 95%CI 0.74–0.97,
321 $p = 0.02$). This effect appeared mainly in the oral subsite (OR weighted median 0.84, 95%CI
322 0.72–0.99, $p = 0.04$). Furthermore, in the analysis of WC on oropharyngeal cancer risk, the
323 weighted mode supported IVW result, providing evidence of a protective effect (OR
324 weighted mode 0.37, 95%CI 0.17–0.83, $p = 0.02$) (**Table 1; Fig. 2**).

325

326 There was clear evidence of heterogeneity in the SNP effect estimates for IVW and MR
327 Egger regression for WHR (Q IVW 213.04, $p = 0.03$; Q MR Egger 209.24, $p = 0.04$), T2D (Q
328 IVW 328.24, $p < 0.01$; Q MR Egger 328.21, $p < 0.01$), FI (Q IVW 32.87, $p < 0.01$; Q MR Egger
329 31.63, $p < 0.01$) and DBP (Q IVW 95.82, $p < 0.01$; Q MR Egger 95.22, $p < 0.01$)
330 (**Supplementary Table 2**). MR-Egger intercepts were not strongly indicative of directional
331 pleiotropy (**Supplementary Table 3**), but there were outliers present on visual inspection of
332 scatter plots (**Supplementary Figs. 11-19**). MR-PRESSO identified 19 outliers for BMI, 2
333 outliers for WC, 12 outliers for WHR, 23 outliers for T2D, 4 outliers for HbA_{1c}, 1 outlier for
334 FG, 3 outliers for FI, 5 outliers for SBP, 7 outliers for DBP (**Supplementary Tables 4-5**). When
335 correcting for these outliers, this yielded effects consistent with the primary IVW analysis
336 except for adiposity and T2D instruments, which demonstrated a protective effect on
337 combined oral and oropharyngeal cancer risk when outliers were excluded: BMI (OR IVW
338 0.77, 95%CI 0.62–0.94, $p = 0.01$, per 1 SD in BMI (4.81 kg/m²)); WC (OR IVW 0.65, 95%CI
339 0.47–0.89, $p = 0.01$, per 1 SD in WC (0.09 unit)), and T2D (OR IVW 0.91, 0.84–0.99, $p = 0.03$,
340 per 1-log unit higher odds of T2D) (**Supplementary Table 6**). Where there was evidence of

341 violation of the NOME assumption for WC, FI, SBP and DBP (i.e., I^2 statistic <0.90)
342 (**Supplementary Table 7**), MR-Egger was performed with SIMEX correction. SIMEX effects
343 were consistent with the null, except for SBP where an increased risk effect on combined
344 oral and oropharyngeal cancer was found (OR IVW 1.15, 95%CI 1.05–1.26, $p < 0.01$, per 1
345 unit mmHg increase in diastolic blood pressure) (**Supplementary Table 8**).

346

347 *Evaluating instrument-risk factor effects*

348 Where there was some evidence for an effect of BMI, WC, WHR, T2D, HbA_{1c} and DBP on
349 oral and oropharyngeal cancer, we carried out further MR analysis to determine causal
350 effects of these metabolic instruments on established risk HNC risk factors. Obesity-related
351 measures showed a strong causal effect on the risk of smoking initiation: BMI (Beta IVW
352 0.21 (standard error (SE) 0.03), $p < 0.001$, per 1 SD increase in BMI (4.81 kg/m²)), WC (Beta
353 IVW 0.21 (SE 0.05), $p < 0.001$, per 1 SD increase in WC (0.09 unit)) and WHR (Beta IVW 0.18
354 (SE 0.03), $p < 0.001$, per 1 SD increase in WHR (0.10 unit)) (**Supplementary Table 9**). There
355 was weaker evidence for an effect of BMI, WC, and genetic liability to T2D on consumption
356 of alcoholic drinks per week: BMI (Beta IVW -0.04 (SE 0.01), $p < 0.01$, per 1 SD increase in
357 BMI (4.81 kg/m²)), WC (Beta IVW -0.09 (SE 0.02), $p < 0.001$, per 1 SD increase in WC (0.09
358 unit)) and T2D (Beta IVW -0.02 (SE 0.01), $p < 0.001$, per 1-log unit higher odds of T2D). BMI
359 (Beta IVW 0.04 (SE 0.01), $p < 0.001$, per 1 SD increase in BMI (4.81 kg/m²)) and WHR (Beta
360 IVW 0.04 (SE 0.02), $p = 0.02$, per 1 SD increase in WHR (0.10 unit)) were also estimated to
361 increase general risk tolerance. Similarly, increased BMI or WHR and genetic liability to T2D
362 were estimated to increase educational attainment (years of schooling): BMI (Beta IVW -
363 0.16 (SE 0.02), $p < 0.001$, per 1 SD increase in BMI (4.81 kg/m²)), WHR (Beta IVW -0.11 (SE
364 0.02), $p < 0.001$, per 1 SD increase in WHR (0.10 unit)), and T2D (Beta IVW -0.02 (SE 0.01), p

365 < 0.01, per 1-log unit higher odds of T2D). However, there was strong evidence of both
366 heterogeneity (**Supplementary Table 10**) and genetic pleiotropy (**Supplementary Table 11**)
367 across most instrument-risk factor effects. With the exception of alcohol drinks per week,
368 the estimated instrument-risk factor effects remained unchanged following the removal of
369 outlier SNPs detected by MR-PRESSO (**Supplementary Table 12**).

370

371 **Discussion**

372

373 In this MR study we found limited evidence to support a causal role of genetically-predicted
374 metabolic traits in oral and oropharyngeal cancer, suggesting the risk may have been
375 previously overestimated in observational studies. Where weak evidence for an effect was
376 found (i.e., a protective effect of HbA_{1c}), these results were not robust to sensitivity analysis,
377 including outlier correction. There was also strong evidence for instrument-risk factor
378 effects, suggesting smoking may be a mediator between obesity and HNC.

379

380 There are several biological mechanisms linking metabolic traits and cancer, but these have
381 not been well explored in HNC⁵⁵⁻⁵⁷. Dysregulated metabolism is likely linked to the
382 probability a cancer develops and progresses, given that tumours must adapt to satisfy the
383 bioenergetic and biosynthetic demands of chronic cell proliferation via metabolic
384 reprogramming, enhancing or suppressing the activity of metabolic pathways relative to
385 that in benign tissue⁵⁸. In the largest pooled analysis of 17 case-control studies, BMI was
386 associated with a higher risk of overall HNC, but when stratified by subsite the effect was
387 mainly in the larynx (HR 1.42, 95%CI 1.19–1.70 per 5 kg/m², $p < 0.001$)¹³. Laryngeal cancer

388 was not included in our study given that GWAS summary data were not available for this
389 subsite and future analysis of this region is therefore warranted. BMI effects on both the
390 oral (HR 1.10, 95%CI 0.97–1.25, $p = 0.14$) and oropharyngeal cancer (HR 0.98, 95%CI 0.84–
391 1.14, $p = 0.77$) subsites were consistent with the effects found in our study (oral cancer OR
392 0.92, 95%CI 0.71–1.19, $p = 0.53$; oropharyngeal cancer OR 0.89, 0.68–1.15, $p = 0.36$)¹³.
393 Conversely, the same pooled analysis found an increased risk for both WC (HR 1.09, 95%CI
394 1.03–1.16, $p = 0.006$) and WHR (HR 1.17, 95%CI 1.02–1.34, $p = 0.02$), mainly in the oral
395 subsite which were not replicated in our MR analysis. Varying patterns of results for these
396 anthropometric measures have been found when stratifying by smoking status within
397 observational studies¹³. The relationship between obesity and HNC is complex. There
398 appears to be a positive association between low BMI ($<18.5 \text{ kg/m}^2$) and HNC risk, and a
399 protective effect of BMI on HNC risk in current smokers but conversely, a higher risk in
400 never smokers¹³. This suggests smoking is a confounder, both as an established risk factor
401 for HNC and in its correlation with weight, with nicotine affecting metabolic energy
402 expenditure, leading to reduced calorie absorption and appetite suppression⁵⁹. Instrument-
403 risk factor effect estimates from this study suggest smoking is also a mediator, through
404 which metabolic traits such as BMI influence HNC risk.

405

406 Despite metabolic syndrome (including hypertension, central obesity, elevated triglyceride,
407 low HDL-C and insulin resistance) being strongly associated with common cancers such as
408 colorectal and breast⁶⁰, this does not appear to be the case in head and neck cancer. A
409 recent prospective study of 474,929 participants from UK Biobank investigating the effect of
410 metabolic syndrome suggested those with the condition had no increased HNC risk (HR
411 1.05, 95%CI 0.90–1.22, $p = 0.560$)¹⁴. No definitive causal effects were detected for

412 individual components of metabolic syndrome components either, supporting our MR
413 results. While another large meta-analysis found individuals with T2D have an elevated risk
414 of oral cancer¹⁹, other more recent studies have found this effect to be mostly in laryngeal
415 subsite (HR 1.25, 95%CI 1.12–1.40) which again we could not investigate in this study²¹.
416 Hypertension is the most consistently reported metabolic trait to have an observational
417 association with HNC risk across the subsites²¹⁻²⁵. We did not identify a clear effect of either
418 SBP or DBP on oral or oropharyngeal cancer using MR, again suggesting the possibility of
419 residual confounding in observational studies.

420

421 MR was employed in this study in an attempt to overcome the drawbacks of conventional
422 epidemiological studies. However, there are a number of limitations with using this
423 approach and if MR assumptions are violated, this too can generate spurious conclusions.
424 While there was no evidence of weak instrument bias (F statistics > 10), there was
425 heterogeneity present in at least four of the instruments (WHR, T2D, FI and DBP). This is
426 expected to some extent, given that we are instrumenting multiple biological pathways that
427 contribute to complex metabolic phenotypes. The use of multiple related instruments for
428 each metabolic trait may, however, provide some additional confidence in the overall
429 findings. Given the low percentage of variation explained (R^2) for some instruments, as well
430 as the relatively small number of oral and oropharyngeal cancer cases, power to detect an
431 effect may have been an issue in some of our analyses.

432

433 As with observational studies, there may be issues of measurement error or
434 misclassification in genetic epidemiology, given BMI is simply a function of mass and height
435 and does not specifically measure adiposity. However, BMI has been shown to be an

436 acceptable proxy when used in large samples sizes, correlating with both total body fat⁶¹
437 and total abdominal adipose tissue⁶², which is thought to present a greater health risk than
438 fat deposited elsewhere. Furthermore, we used a range of adiposity measures including WC
439 and WHR, which may be better proxies of abdominal adiposity, compared to BMI⁶³. SNPs
440 used to proxy these metabolic traits, particularly obesity-related measures BMI, WC and
441 WHR were strongly associated with smoking. Given the heterogeneity of these complex
442 metabolic traits, future work could further examine their pathway specific effects⁶⁴.

443

444 **Conclusion**

445

446 Overall, there was limited evidence for an effect of genetically-proxied metabolic traits on
447 oral and oropharyngeal cancer risk. These findings suggest metabolic traits may not be
448 effective modifiable risk factors to prioritise as part of future prevention strategies in head
449 and neck cancer. The effect of metabolic traits on the risk of this disease may have been
450 overestimated in previous observational studies, but these cannot be directly compared
451 given the differences in methodological approaches and the interpretation of estimates.
452 Smoking appears to act as a mediator in the relationship between obesity and HNC.
453 Although there is no clear evidence that changing body mass will reduce or increase the risk
454 of HNC directly, dental and medical teams should be aware of the risk of smoking in those
455 who are overweight and therefore the greater risk of cancer when providing smoking
456 cessation and appropriate weight loss advice.

457

458

459 References

460

461 1 Sung, H. *et al.* Global cancer statistics 2020: GLOBOCAN estimates of incidence and
462 mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for*
463 *Clinicians*, doi:<https://doi.org/10.3322/caac.21660> (2021).

464 2 Johnson, D. E. *et al.* Head and neck squamous cell carcinoma. *Nature Reviews*
465 *Disease Primers* **6**, 92, doi:10.1038/s41572-020-00224-3 (2020).

466 3 Hashibe, M. *et al.* Interaction between Tobacco and Alcohol Use and the Risk of
467 Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer
468 Epidemiology Consortium. *Cancer Epidem Biomar* **18**, 541-550, doi:10.1158/1055-
469 9965.Epi-08-0347 (2009).

470 4 Gillison, M. L., Chaturvedi, A. K., Anderson, W. F. & Fakhry, C. Epidemiology of
471 Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. *J Clin*
472 *Oncol* **33**, 3235-3242, doi:10.1200/JCO.2015.61.6995 (2015).

473 5 World Health Organization (WHO). *WHO European Regional Obesity Report 2022*.
474 *[Internet] [cited 2022 Jun 06], 2022).*

475 6 Thomas, S. J., Penfold, C. M., Waylen, A. & Ness, A. R. The changing aetiology of head
476 and neck squamous cell cancer: A tale of three cancers? *Clin Otolaryngol* **43**, 999-
477 1003, doi:10.1111/coa.13144 (2018).

- 478 7 Conway, D. I., Purkayastha, M., Chestnutt, I. G. The changing epidemiology of oral
479 cancer: definitions, trends, and risk factors. *British Dental Journal* **225**, 867-873,
480 doi:10.1038/sj.bdj.2018.922 (2018).
- 481 8 Carreras-Torres, R. *et al.* Role of obesity in smoking behaviour: Mendelian
482 randomisation study in UK Biobank. *BMJ (Clinical research ed.)* **361**, k1767-k1767,
483 doi:10.1136/bmj.k1767 (2018).
- 484 9 Carter, A. R. *et al.* Combined Association of Body Mass Index and Alcohol
485 Consumption With Biomarkers for Liver Injury and Incidence of Liver Disease: A
486 Mendelian Randomization Study. *JAMA Network Open* **2**, e190305-e190305,
487 doi:10.1001/jamanetworkopen.2019.0305 (2019).
- 488 10 Carter, A. R. *et al.* Understanding the consequences of education inequality on
489 cardiovascular disease: mendelian randomisation study. *BMJ* **365**, l1855,
490 doi:10.1136/bmj.l1855 (2019).
- 491 11 Centers for Disease Control and Prevention. *Obesity and Cancer [Internet] [cited*
492 *2022 Jun 18]*,
493 <https://www.cdc.gov/cancer/obesity/index.htm#:~:text=Being%20overweight%20o>
494 [r%20having%20obesity,the%20United%20States%20each%20year.](https://www.cdc.gov/cancer/obesity/index.htm#:~:text=Being%20overweight%20or%20having%20obesity,the%20United%20States%20each%20year.)> (2021).
- 495 12 Davey, R. C. The obesity epidemic: too much food for thought? *British Journal of*
496 *Sports Medicine* **38**, 360-363, doi:10.1136/bjism.2003.007443 (2004).

- 497 13 Gaudet, M. M. *et al.* Anthropometry and head and neck cancer: a pooled analysis of
498 cohort data. *Int J Epidemiol* **44**, 673-681, doi:<https://dx.doi.org/10.1093/ije/dyv059>
499 (2015).
- 500 14 Jiang, H. *et al.* The effect of metabolic syndrome on head and neck cancer incidence
501 risk: a population-based prospective cohort study. *Cancer & metabolism* **9**, 25-25,
502 doi:<https://dx.doi.org/10.1186/s40170-021-00261-w> (2021).
- 503 15 Diaz, Y. *et al.* Body mass index and waist circumference in relation to the risk of 26
504 types of cancer: a prospective cohort study of 3.5 million adults in Spain. *BMC*
505 *Medicine* **19**, 10-10, doi:<http://dx.doi.org/10.1186/s12916-020-01877-3> (2021).
- 506 16 Cao, Z. *et al.* Association of obesity status and metabolic syndrome with site-specific
507 cancers: a population-based cohort study. *Brit J Cancer* **123**, 1336-1344,
508 doi:<http://dx.doi.org/10.1038/s41416-020-1012-6> (2020).
- 509 17 Gribsholt, S. B. *et al.* Hospital-diagnosed overweight and obesity related to cancer
510 risk: a 40-year Danish cohort study. *Journal of Internal Medicine* **287**, 435-447,
511 doi:<http://dx.doi.org/10.1111/joim.13013> (2020).
- 512 18 Ward, H. A. *et al.* Measured Adiposity in Relation to Head and Neck Cancer Risk in
513 the European Prospective Investigation into Cancer and Nutrition. *Cancer*
514 *epidemiology, biomarkers & prevention : a publication of the American Association*
515 *for Cancer Research, cosponsored by the American Society of Preventive Oncology*
516 **26**, 895-904, doi:<https://dx.doi.org/10.1158/1055-9965.EPI-16-0886> (2017).

- 517 19 Gong, Y., Wei, B., Yu, L. & Pan, W. Type 2 diabetes mellitus and risk of oral cancer
518 and precancerous lesions: a meta-analysis of observational studies. *Oral oncology*
519 **51**, 332-340, doi:<https://dx.doi.org/10.1016/j.oraloncology.2015.01.003> (2015).
- 520 20 Saarela, K. *et al.* Cancer incidence among Finnish people with type 2 diabetes during
521 1989-2014. *Eur J Epidemiol* **34**, 259-265, doi:[https://dx.doi.org/10.1007/s10654-018-](https://dx.doi.org/10.1007/s10654-018-0438-0)
522 [0438-0](https://dx.doi.org/10.1007/s10654-018-0438-0) (2019).
- 523 21 Kim, H.-B., Kim, G.-J., Han, K.-d. & Joo, Y.-H. Changes in metabolic syndrome status
524 and risk of laryngeal cancer: A nationwide cohort study. *PLoS ONE* **16**, e0252872-
525 e0252872, doi:<http://dx.doi.org/10.1371/journal.pone.0252872> (2021).
- 526 22 Kim, S.-Y., Han, K.-d. & Joo, Y.-H. Metabolic Syndrome and Incidence of Laryngeal
527 Cancer: A Nationwide Cohort Study. *Scientific reports* **9**, 667,
528 doi:<https://dx.doi.org/10.1038/s41598-018-37061-0> (2019).
- 529 23 Stocks, T. *et al.* Blood pressure and risk of cancer incidence and mortality in the
530 Metabolic Syndrome and Cancer Project. *Hypertension (Dallas, Tex. : 1979)* **59**, 802-
531 810, doi:<https://dx.doi.org/10.1161/HYPERTENSIONAHA.111.189258> (2012).
- 532 24 Christakoudi, S. *et al.* Blood pressure and risk of cancer in the European Prospective
533 Investigation into Cancer and Nutrition. *Int J Cancer* **146**, 2680-2693,
534 doi:<http://dx.doi.org/10.1002/ijc.32576> (2020).
- 535 25 Seo, J.-H., Kim, Y.-D., Park, C.-S., Han, K.-d. & Joo, Y.-H. Hypertension is associated
536 with oral, laryngeal, and esophageal cancer: a nationwide population-based study.

- 537 *Scientific reports* **10**, 10291, doi:<https://dx.doi.org/10.1038/s41598-020-67329-3>
538 (2020).
- 539 26 Smith, G. D. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology
540 contribute to understanding environmental determinants of disease? *Int J Epidemiol*
541 **32**, 1-22, doi:10.1093/ije/dyg070 (2003).
- 542 27 Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal
543 inference in epidemiological studies. *Hum Mol Genet* **23**, R89-98,
544 doi:10.1093/hmg/ddu328 (2014).
- 545 28 Sanderson, E. *et al.* Mendelian randomization. *Nature Reviews Methods Primers* **2**, 6,
546 doi:10.1038/s43586-021-00092-5 (2022).
- 547 29 Gormley, M. *et al.* Using genetic variants to evaluate the causal effect of cholesterol
548 lowering on head and neck cancer risk: A Mendelian randomization study. *PLOS*
549 *Genetics* **17**, e1009525, doi:10.1371/journal.pgen.1009525 (2021).
- 550 30 Pulit, S. L. *et al.* Meta-analysis of genome-wide association studies for body fat
551 distribution in 694 649 individuals of European ancestry. *Hum Mol Genet* **28**, 166-
552 174, doi:10.1093/hmg/ddy327 (2019).
- 553 31 Shungin, D. *et al.* New genetic loci link adipose and insulin biology to body fat
554 distribution. *Nature* **518**, 187-196, doi:10.1038/nature14132 (2015).
- 555 32 Vujkovic, M. *et al.* Discovery of 318 new risk loci for type 2 diabetes and related
556 vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis.
557 *Nat Genet* **52**, 680-691, doi:10.1038/s41588-020-0637-y (2020).

- 558 33 Lagou, V. *et al.* Sex-dimorphic genetic effects and novel loci for fasting glucose and
559 insulin variability. *Nature Communications* **12**, 24, doi:10.1038/s41467-020-19366-9
560 (2021).
- 561 34 Wheeler, E. *et al.* Impact of common genetic determinants of Hemoglobin A1c on
562 type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic
563 genome-wide meta-analysis. *PLoS Med* **14**, e1002383,
564 doi:10.1371/journal.pmed.1002383 (2017).
- 565 35 Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci
566 associated with blood pressure traits. *Nat Genet* **50**, 1412-1425,
567 doi:10.1038/s41588-018-0205-x (2018).
- 568 36 Lesueur, C. *et al.* Genome-wide association analyses identify new susceptibility loci
569 for oral cavity and pharyngeal cancer. *Nat Genet* **48**, 1544-1550,
570 doi:10.1038/ng.3685 (2016).
- 571 37 Dudding, T. *et al.* Assessing the causal association between 25-hydroxyvitamin D and
572 the risk of oral and oropharyngeal cancer using Mendelian randomization. *Int J*
573 *Cancer* **143**, 1029-1036, doi:10.1002/ijc.31377 (2018).
- 574 38 Consortium, O. Consortium launches genotyping effort. *Cancer Discov* **3**, 1321-1322,
575 doi:10.1158/2159-8290.CD-NB2013-159 (2013).
- 576 39 Pers, T. H., Timshel, P. & Hirschhorn, J. N. SNPsnap: a Web-based tool for
577 identification and annotation of matched SNPs. *Bioinformatics* **31**, 418-420,
578 doi:10.1093/bioinformatics/btu655 (2014).

- 579 40 Wald, A. The Fitting of Straight Lines if Both Variables are Subject to Error. *The*
580 *Annals of Mathematical Statistics* **11**, 284-300, 217 (1940).
- 581 41 Hemani, G., Bowden, J. & Smith, G. D. Evaluating the potential role of pleiotropy in
582 Mendelian randomization studies. *Hum Mol Genet* **27**, R195-R208,
583 doi:10.1093/hmg/ddy163 (2018).
- 584 42 Bowden, J., Smith, G. D., Haycock, P. C. & Burgess, S. Consistent Estimation in
585 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
586 Estimator. *Genet Epidemiol* **40**, 304-314, doi:10.1002/gepi.21965 (2016).
- 587 43 Hartwig, F. P., Smith, G. D. & Bowden, J. Robust inference in summary data
588 Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol*
589 **46**, 1985-1998, doi:10.1093/ije/dyx102 (2017).
- 590 44 Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
591 instruments: effect estimation and bias detection through Egger regression. *Int J*
592 *Epidemiol* **44**, 512-525, doi:10.1093/ije/dyv080 (2015).
- 593 45 Lawlor DA, W. K., Borges MC, Palmer T, Hartwig FP, Hemani G, Bowden JA. . A
594 Mendelian Randomization dictionary: Useful definitions and descriptions for
595 undertaking, understanding and interpreting Mendelian Randomization studies.
596 doi:doi:10.31219/osf.io/6yzs7 (2019).
- 597 46 Bowden, J. *et al.* Assessing the suitability of summary data for two-sample
598 Mendelian randomization analyses using MR-Egger regression: the role of the I-2
599 statistic. *Int J Epidemiol* **45**, 1961-1974, doi:10.1093/ije/dyw220 (2016).

- 600 47 Brion, M. J., Shakhbazov, K. & Visscher, P. M. Calculating statistical power in
601 Mendelian randomization studies. *Int J Epidemiol* **42**, 1497-1501,
602 doi:10.1093/ije/dyt179 (2013).
- 603 48 Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian
604 randomization: using genes as instruments for making causal inferences in
605 epidemiology. *Stat Med* **27**, 1133-1163, doi:10.1002/sim.3034 (2008).
- 606 49 Bowden, J. *et al.* Improving the visualization, interpretation and analysis of two-
607 sample summary data Mendelian randomization via the Radial plot and Radial
608 regression. *Int J Epidemiol* **47**, 1264-1278, doi:10.1093/ije/dyy101 (2018).
- 609 50 Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Publisher Correction: Detection of
610 widespread horizontal pleiotropy in causal relationships inferred from Mendelian
611 randomization between complex traits and diseases. *Nat Genet* **50**, 1196,
612 doi:10.1038/s41588-018-0164-2 (2018).
- 613 51 Liu, M. Z. *et al.* Association studies of up to 1.2 million individuals yield new insights
614 into the genetic etiology of tobacco and alcohol use. *Nat Genet* **51**, 237,
615 doi:10.1038/s41588-018-0307-5 (2019).
- 616 52 Karlsson Linner, R. *et al.* Genome-wide association analyses of risk tolerance and
617 risky behaviors in over 1 million individuals identify hundreds of loci and shared
618 genetic influences. *Nat Genet* **51**, 245-257, doi:10.1038/s41588-018-0309-3 (2019).

- 619 53 Gormley, M. *et al.* Investigating the effect of sexual behaviour on oropharyngeal
620 cancer risk: a methodological assessment of Mendelian randomization. *BMC*
621 *Medicine* **20**, 40, doi:10.1186/s12916-022-02233-3 (2022).
- 622 54 Lee, J. J. *et al.* Gene discovery and polygenic prediction from a genome-wide
623 association study of educational attainment in 1.1 million individuals. *Nat Genet* **50**,
624 1112-1121, doi:10.1038/s41588-018-0147-3 (2018).
- 625 55 Tseng, K. S., Lin, C., Lin, Y. S. & Weng, S. F. Risk of head and neck cancer in patients
626 with diabetes mellitus: a retrospective cohort study in Taiwan. *JAMA Otolaryngol*
627 *Head Neck Surg* **140**, 746-753, doi:10.1001/jamaoto.2014.1258 (2014).
- 628 56 Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? *Nat Rev*
629 *Cancer* **4**, 891-899, doi:10.1038/nrc1478 (2004).
- 630 57 Grimberg, A. Mechanisms by which IGF-I may promote cancer. *Cancer Biol Ther* **2**,
631 630-635 (2003).
- 632 58 DeNicola, G. M. & Cantley, L. C. Cancer's Fuel Choice: New Flavors for a Picky Eater.
633 *Mol Cell* **60**, 514-523, doi:10.1016/j.molcel.2015.10.018 (2015).
- 634 59 Williamson, D. F. *et al.* Smoking Cessation and Severity of Weight Gain in a National
635 Cohort. *New Engl J Med* **324**, 739-745, doi:10.1056/nejm199103143241106 (1991).
- 636 60 Esposito, K., Chiodini, P., Colao, A., Lenzi, A. & Giugliano, D. Metabolic syndrome and
637 risk of cancer: a systematic review and meta-analysis. *Diabetes care* **35**, 2402-2411,
638 doi:10.2337/dc12-0336 (2012).

639 61 Browning, L. M. *et al.* Measuring abdominal adipose tissue: comparison of simpler
640 methods with MRI. *Obes Facts* **4**, 9-15, doi:10.1159/000324546 (2011).

641 62 Ross, R., Léger, L., Morris, D., de Guise, J. & Guardo, R. Quantification of adipose
642 tissue by MRI: relationship with anthropometric variables. *J Appl Physiol (1985)* **72**,
643 787-795, doi:10.1152/jappl.1992.72.2.787 (1992).

644 63 Lee, C. M., Huxley, R. R., Wildman, R. P. & Woodward, M. Indices of abdominal
645 obesity are better discriminators of cardiovascular risk factors than BMI: a meta-
646 analysis. *J Clin Epidemiol* **61**, 646-653, doi:10.1016/j.jclinepi.2007.08.012 (2008).

647 64 Udler, M. S. *et al.* Type 2 diabetes genetic loci informed by multi-trait associations
648 point to disease mechanisms and subtypes: A soft clustering analysis. *PLoS Med* **15**,
649 e1002654, doi:10.1371/journal.pmed.1002654 (2018).

650

651 **Ethics approval and consent to participate**

652 All studies included as part of the GAME-ON network obtained approval and consent from
653 their respective institutions.

654

655 **Consent for publication**

656 Not applicable.

657

658 **Availability of data and materials**

659 Summary-level analysis was conducted using publicly available GWAS data as cited. Full
660 summary statistics for the GAME-ON outcome data GWAS can be accessed via dbGAP

661 (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1, August

662 2017 at: [https://www.ncbi.nlm.nih.gov/projects/gap/cgi-](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001202.v1.p1)
663 [bin/study.cgi?study_id=phs001202.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001202.v1.p1)). There is one selected publication by Lesseur et
664 al. related to this data ³⁶. Exposure data is publicly available from the relevant studies and
665 via the IEU Open GWAS (<https://gwas.mrcieu.ac.uk/>). MR analyses were conducted using
666 the “TwoSampleMR” package in R (version 3.5.3). A copy of the code and all files used in
667 this analysis is available at GitHub
668 (https://github.com/MGormley12/metabolic_trait_hnc_mr.git).

669

670 **Competing interests**

671 The authors declare that they have no competing interests

672

673 **Funding**

674 M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is
675 currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship.
676 This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z].
677 For the purpose of open access, the author has applied a CC BY public copyright licence to
678 any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC
679 research fellow at the University of Bristol. J.T. is supported by an Academy of Medical
680 Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust,
681 Global Challenges Research Fund (GCRF), the Government Department of Business, Energy
682 and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079). A.R.N.
683 was supported by the National Institute for Health Research (NIHR) Bristol Biomedical
684 Research Centre which is funded by the National Institute for Health Research (NIHR) and is
685 a partnership between University Hospitals Bristol NHS Foundation Trust and the University

686 of Bristol. Department of Health and Social Care disclaimer: The views expressed are those
687 of the authors and not necessarily those of the NHS, the NIHR or the Department of Health
688 and Social Care. This publication presents data from the Head and Neck 5000 which
689 contributes to international VOYAGER and HEADSpAcE head and neck cancer consortia. The
690 Head and Neck 5000 study was a component of independent research funded by the
691 National Institute for Health Research (NIHR) under its Programme Grants for Applied
692 Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of
693 the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
694 Core funding was also provided through awards from Above and Beyond, University
695 Hospitals Bristol and Weston Research Capability Funding and the NIHR Senior Investigator
696 award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research
697 UK Programme Grant, the Integrative Cancer Epidemiology Programme (C18281/A20919).
698 The VOYAGER study was supported in part by the US National Institute of Dental and
699 Craniofacial Research (NIDCR; R01 DE025712). The genotyping of the HNC cases and
700 controls was performed at the Center for Inherited Disease Research (CIDR) and funded by
701 the US National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0).
702 E.E.V, C.B. and D.L. are supported by Diabetes UK (17/0005587). E.E.V, and C.B. are
703 supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer
704 Research Fund International grant programme (IIG_2019_2009). M.G., T.D., G.D.S, E.E.V.,
705 R.C.R, and C.B. are part of the Medical Research Council Integrative Epidemiology Unit at
706 the University of Bristol supported by the Medical Research Council (MC_UU_00011/1,
707 MC_UU_00011/5, MC_UU_00011/6, MC_UU_00011/7).

708

709 **Authors' contributions**

710 M.G., E.E.V., R.C.R. and C.B. conceived the study and M.G. carried out data curation and
711 analysis. Head and neck cancer summary genetic data was obtained through multiple
712 collaborations from studies lead by A.R.N., S.J.T., and M.P. as well as members of VOYAGER
713 and HEADSpAcE consortia. The initial manuscript was drafted by M.G., E.E.V. and C.B..
714 Expert guidance on MR methodology was provided by T.D., C.B. and G.D.S. All authors M.G.,
715 T.D., S.J.T., J.T., A.R.N., M.P., D.L., G.D.S., R.C.R., E.E.V., and C.B. contributed to the
716 interpretation of the results and critical revision of the manuscript. All authors read and
717 approved the final manuscript. M.G. supervisory team includes R.C.R., E.E.V., J.T., A.R.N and
718 G.D.S.